Four patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Sep 2037. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Sep 2037
Next term end
3
Patent families
When these terms end
Each bar runs from grant to computed term end. 2020 to 2038.
US 10,973,773
Dactinomycin Compositions and Methods for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia
Sep 13, 2037
US 11,975,111
Dactinomycin Compositions and Methods for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia
Sep 13, 2037
US 10,758,541
Formulations of Milciclib and Therapeutic Combinations of the Same for Use in the Treatment of Cancer
Nov 6, 2038
20242028203220362038
10 pending applications: term is not computable until grant.Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Oct 2037 · High confidence
Also notable
Ends Sep 2037 · High confidence
Also notable
Ends Nov 2038 · High confidence
ANTI-CD3 Antibody Formulations
US 10,688,186
The earliest of the three still in force, granted 2020 and renewed since. Its term ends first, in 2037.
Dactinomycin Compositions and Methods for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia
US 10,973,773
The newest of the three, granted 2021. It anchors the portfolio to 2037, later than anything else here.
Formulations of Milciclib and Therapeutic Combinations of the Same for Use in the Treatment of Cancer
US 10,758,541
The earliest of the three still in force, granted 2020 and renewed since. Its term ends first, in 2038.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 7, 2027The maintenance fee for Dactinomycin Compositions and Methods for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia (US 11,975,111) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Dactinomycin Compositions and Methods for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia | 2 in force | to Sep 2037 |
| Formulations of Milciclib and Therapeutic Combinations of the Same for Use in the Treatment of Cancer | 1 in force | to Nov 2038 |
| ANTI-CD3 Antibody Formulations | 1 in force | to Oct 2037 |
Patents held now
Soonest term end first.
Showing 1 to 4 of 4
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,973,773 | Dactinomycin Compositions and Methods for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia In force · High confidence | In force | High confidence | |
| US 11,975,111 | Dactinomycin Compositions and Methods for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia In force · High confidence | In force | High confidence | |
| US 10,688,186 | ANTI-CD3 Antibody Formulations In force · High confidence | In force | High confidence | |
| US 10,758,541 | Formulations of Milciclib and Therapeutic Combinations of the Same for Use in the Treatment of Cancer In force · High confidence | In force | High confidence |
Also on record, not counted in the 4: 10 applications pending · 9 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.